Fiscal Period | 2025 | 2024 | 2023 | 2022 |
---|---|---|---|---|
Period End Date | Mar 25 | Mar 24 | Mar 23 | Mar 22 |
Total Operating Expense | 2,636.37 | 2,778.00 | 2,513.91 | 2,599.03 |
Other Net | 4.77 | 4.85 | -0.37 | 3.45 |
Diluted Weighted Average Shares | 16.94 | 16.94 | 16.94 | 16.94 |
Gain( Loss)on Saleof Assets | 4.69 | 20.58 | 9.67 | 31.72 |
Depreciation/ Amortization | 66.66 | 69.54 | 65.62 | 68.04 |
Operating Income | 1,112.84 | 675.71 | 737.81 | 679.00 |
Net Income | 927.58 | 589.96 | 610.69 | 1,694.72 |
Income Availableto Com Excl Extra Ord | 927.58 | 589.96 | 607.64 | 380.77 |
Other Operating Expenses Total | 60.64 | 61.01 | 52.24 | 47.06 |
Net Income Before Taxes | 1,259.88 | 816.19 | 836.40 | 779.05 |
Interest Exp( Inc) Net- Operating Total | 0.13 | 0.14 | 0.14 | 0.14 |
Net Income After Taxes | 927.58 | 589.96 | 607.64 | 380.77 |
Income Availableto Com Incl Extra Ord | 927.58 | 589.96 | 610.69 | 1,694.72 |
Costof Revenue Total | 1,512.30 | 1,457.10 | 1,394.28 | 1,482.14 |
Gross Profit | 2,236.91 | 1,996.61 | 1,857.44 | 1,795.89 |
Interest Inc( Exp) Net- Non- Op Total | 137.58 | 115.05 | 89.29 | 64.87 |
Diluted Net Income | 927.58 | 589.96 | 610.69 | 1,694.72 |
DPS- Common Stock Primary Issue | 42.00 | 32.00 | 32.00 | 30.00 |
Provisionfor Income Taxes | 332.30 | 226.23 | 228.76 | 398.28 |
period Type | - | - | - | - |
Net Income Before Extra Items | 927.58 | 589.96 | 607.64 | 380.77 |
Total Revenue | 3,749.21 | 3,453.71 | 3,251.72 | 3,278.03 |
period Length | 12.00 | 12.00 | 12.00 | 12.00 |
Revenue | 3,749.21 | 3,453.71 | 3,251.72 | 3,278.03 |
Selling/ General/ Admin Expenses Total | 996.64 | 1,026.91 | 991.00 | 981.81 |
Diluted Normalized EPS | 54.55 | 40.92 | 35.91 | 22.13 |
Diluted EPS Excluding Extra Ord Items | 54.76 | 34.83 | 35.87 | 22.48 |
Total Extraordinary Items | - | 0.00 | 3.04 | 1,313.95 |
Unusual Expense( Income) | - | 163.30 | 10.61 | 19.82 |
Glaxosmithkline Pharmaceutical Dividend Glaxosmithkline Pharmaceutical Bonus Glaxosmithkline Pharmaceutical News Glaxosmithkline Pharmaceutical AGM Glaxosmithkline Pharmaceutical Rights Glaxosmithkline Pharmaceutical Splits Glaxosmithkline Pharmaceutical Board Meetings Glaxosmithkline Pharmaceutical Key Metrics Glaxosmithkline Pharmaceutical Shareholdings Glaxosmithkline Pharmaceutical Balance Sheet Glaxosmithkline Pharmaceutical Cashflow Glaxosmithkline Pharmaceutical Q1 Results Glaxosmithkline Pharmaceutical Q2 Results Glaxosmithkline Pharmaceutical Q3 Results Glaxosmithkline Pharmaceutical Q4 Results
Top GainersTop LosersIndian IndicesBSE Active StocksNSE Active Stocks